Editorial Open Access
Copyright ©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Cardiol. Oct 26, 2010; 2(10): 308-315
Published online Oct 26, 2010. doi: 10.4330/wjc.v2.i10.308
Management and therapy of vasovagal syncope: A review
Muhammet Ali Aydin, Tushar V Salukhe, Iris Wilke, Stephan Willems, Department of Electrophysiology, University Heart Center Hamburg, Martinistraße 52, Hamburg 20246, Germany
Author contributions: Aydin MA, Salukhe TV, Wilke I and Willems S wrote the manuscript.
Correspondence to: Muhammet Ali Aydin, MD, Department of Electrophysiology, University Heart Center Hamburg, Martinistraße 52, Hamburg 20246, Germany. aydin@uke.de
Telephone: +40-7410-54120 Fax: +40-7410-58570
Received: May 12, 2010
Revised: August 12, 2010
Accepted: August 19, 2010
Published online: October 26, 2010


Vasovagal syncope is a common cause of recurrent syncope. Clinically, these episodes may present as an isolated event with an identifiable trigger, or manifest as a cluster of recurrent episodes warranting intensive evaluation. The mechanism of vasovagal syncope is incompletely understood. Diagnostic tools such as implantable loop recorders may facilitate the identification of patients with arrhythmia mimicking benign vasovagal syncope. This review focuses on the management of vasovagal syncope and discusses the non-pharmacological and pharmacological treatment options, especially the use of midodrine and selective serotonin reuptake inhibitors. The role of cardiac pacing may be meaningful for a subgroup of patients who manifest severe bradycardia or asystole but this still remains controversial.

Key Words: Vasovagal syncope, Midodrine, Adrenergic β-antagonists, Serotonin uptake inhibitors


Syncope is a common clinical problem challenging both cardiologists and general practitioners with an annual incidence of 1.3 to 2.7 events per thousand population[1]. The aim of this review is to present a review on the management and treatment of vasovagal syncope. It covers new aspects presented in current guidelines for the diagnosis and management[2], and new data for risk stratification[3].

The main aim of the evaluation is to distinguish patients with a benign cause like vasovagal syncope from patients with life-threatening conditions like arrhythmias, severe cardiovascular diseases or neurological causes to minimize the risk of sudden cardiac death. There is still a high unexplained syncope rate in all settings, so new strategies for evaluation and diagnosis are crucial.


Syncope is defined as a transient and self-terminating loss of consciousness (LOC) with rapid onset, short duration combined with spontaneous, prompt and complete recovery. Syncope is characterized by global cerebral hypoperfusion[2]. It is essential to discriminate syncope from other disorders with transient LOC, e.g. seizure, hypoglycemia, catalepsy or aborted sudden cardiac death. In most cases a detailed medical history and information about the trigger situation allows identification of cause. To avoid confusion, syncope should not be used as a synonym for transient loss of consciousness. The term ‘pre-syncope’ or ‘near-syncope’ is used to describe a state that resembles the prodrome of syncope but which is not followed by LOC[2]. It is important to underline that doubts remain as to whether the pathophysiological mechanisms of pre-syncope are the same as in syncope. Figure 1 displays a pathophysiological classification defined in the new guidelines: the first mechanism is a reflex causing bradycardia induced by typical triggers. The second is induced by inadequate venous return, due to volume depletion or venous pooling. The third is due to cardiovascular causes, such as arrhythmia and structural diseases[2].

Figure 1
Figure 1 Classification of syncope.

The reflex syncope includes different types of syncope which all show a typical trigger circumstance and an induction of cardiovascular reflexes. Activation of these sympathetic and parasympathetic reflex loops instigates either hypotension (vasodepressor type) or bradycardia (cardioinhibitory type) or both (mixed type)[4]. The term neurocardiogenic syncope should not be used any longer.

Current guidelines subclassify reflex syncope into vasovagal, situational, carotid sinus syncope, and atypical reflex syncopes[2]. ‘Vasovagal’ syncope, also known as the ‘common faint’, is mediated by emotion or by orthostatic stress. It is usually preceded by prodromal symptoms of autonomic activation (sweating, pallor, nausea)[2].


Epidemiological studies indicate that up to 40% of the general population has experienced at least one episode of syncope in their lifetime[5-9]. Savage et al[1] reported an incidence of 1.3 per 1000 person-years for at least one syncopal episode and 1.0 per 1000 person-years in subjects with criteria for isolated syncope (likely vasovagal syncope). Soteriades et al[7] reported an overall incidence of a first report of syncope in 6.2 per 1000 person-years. Recently a large database with reasons for encounters of general practitioners in the Netherlands revealed that 2 to 9 per 1000 encounters are due to blackouts or fainting[10].

A reflex syncope is the most frequent cause of syncope in any setting and age group[2] representing 21% of all syncopes in the general population[7], 35%-48% of syncopes presenting to the emergency department[11] and 56%-78% of syncopes in a specialized syncope unit[11,12]. The vasovagal syncope is by far the most common reflex syncope in young patients. Clinical studies reveal a peak incidence between 10 and 30 years of age[5,13]. The epidemiology of syncope is different in relation to age. In younger patients a neurally-mediated mechanism is the most common cause, while in older patients cardiovascular causes are more prevalent. The actual incidence and prevalence of vasovagal syncope in the elderly has not yet been established, but vasovagal syncope is now being diagnosed with increasing frequency in this age group, suggesting a bimodal age distribution of vasovagal syncope[14]. In the elderly, cardiac causes, orthostatic and postprandial hypotension, and the effects of medications are common, whereas typical vasovagal syncope is less frequent[10]. In the older patients the diagnostic work-up is more complex, the prognosis may not necessarily follow the benign course commonly observed in younger patients and therapy often remains uncertain. In this paper the management and treatment of vasovagal syncope focuses on patients with vasovagal syncope.


The pathophysiology of the hypotension/bradycardia reflex responsible for vasovagal syncope is not completely understood. Central as well as peripheral mechanisms have been implicated in its pathogenesis; however their relative contribution is not fully elucidated. The different clinical presentation of vasovagal syncope, the variable outcome and the syncope tilt-induced with different drugs such as isoproterenol, nitroglycerin, or clomipramine, acting at very different levels of the reflex pathway, suggest that complex pathophysiological mechanisms may cause a vasovagal reaction.

The pathophysiology of vasovagal syncope is characterized by a reflex activation triggering a rapid decrease in heartbeat and a reduction of vascular tone[15]. The concept of depressor reflexes originating in the heart was first described by von Bezold in 1867 and was later revised by Jarisch in 1937. The change to an upright position causes venous pooling: up to 800 mL of blood flows down to the legs. By activation of the autonomous system contractility and heartbeat increases to maintain sufficient circulating heart volume[16]. In the first moments of a vasovagal syncope an empty heart is seen in echocardiographic investigations because of an acute loss of preload (‘empty heart’ syndrome)[17].

Mechanoreceptors located in the wall of the left ventricle, the aorta and the pulmonary trunk were activated. Sensory receptors with non-myelinated vagal afferent pathways (found mainly in the left ventricle but also in the bladder, lungs or esophagus), detect and control cardiac filling to preserve a sufficient vascular tone. Stimulation of these inhibitory cardiac receptors by stretch forces, chemical substances or drugs heightens parasympathetic activity and inhibits sympathetic activity[18]. Vagal c-type nerve fibers connect the heart with the brainstem. Within the brainstem vagal neurons are stimulated and the activity of cells of the sympathetic nervous system is depressed.

Activation of this reflex mechanism provokes bradycardia, vasodilatation and hypotension. Furthermore, non-cardiac, humoral effects are part of the efferent leg of this reflex loop: e.g. renin, catecholamine and glucocorticoid secretion is augmented[19]. Conversely, a decrease in the activity of these inhibitory sensory receptors stimulates an increase in sympathetic activity, vascular resistance, plasma renin activity and vasopressin. The main trigger for this reflex loops is a reduction in venous return during upright position. Factors which augment this reflex response include extravascular factors such as a warm environment or psychological stress[20].

The different types of vasovagal syncope are explained by different degrees of activation or depression of the autonomous nervous system: a more intensive activation of the parasympathetic nervous system provokes bradycardia, the main symptom of cardioinhibitory vasovagal syncope. The primarily acute loss of sympathetic stimulation is the reason for the drop of blood pressure, the main symptom of the vasodepressive type. Nevertheless in most cases a combined mechanism is seen. Recent data in patients with vasovagal syncope undergoing tilt testing potentiated by intravenous clomipramine, suggested that the neurally-mediated syncope can not only be provoked by increased sympathetic nerve tone, but can also be initiated by some central nervous system triggers of the serotoninergic system[21]. In addition, in older subjects the mechanisms of tilt-induced syncope seems to be different than in younger subjects, justifying at least partially the different clinical pattern of neurally-mediated reflex syncope.


Although most patients display typical conditions and signs of a vasovagal syncope such as symptom onset during standing, light-headedness and full recovery after a few minutes, up to 30% have an atypical presentation. In some cases syncope occurs without any prodromal symptoms[22]. The loss of consciousness is usually brief and fatigue is rarely seen. In the case of longer lasting cerebral hypoperfusion seizure-like movements are observed, imitating an epileptic seizure.

Symptoms before fainting are caused by reduced cerebral perfusion. The patients complain of fatigue, weakness, dizziness, wetness of the skin, a dimming of vision, and sometimes tinnitus and complete loss of vision. Some patients suffer trauma, though severe traumatic injuries are rare.

Basic diagnostics

Many sophisticated tools, provocation tests and diagnostic methods have been introduced to diagnose vasovagal syncope though none are definitive. An exhaustive in-depth history and detailed examination are essential for diagnosis[23,24]. The identification of life-threatening conditions in which syncope is only the indicator of an underlying cardiovascular disease is paramount.

Most experts recommend a standard 12-lead electrocardiography (ECG) as a routine investigation to rule out heart rhythm disturbances[22]. In any patient with a history of cardiac disease and/or an abnormal examination, e.g. heart murmurs, echocardiography and/or stress-ECG is justified (Figure 2).

Figure 2
Figure 2 Diagnostic pathway in syncope. 1Structural heart disease (e.g. valvular, myocardial infarction) or vascular diseases (e.g. pulmonary embolism, aortic disease). ECG: Electrocardiography; RR: Non-invasive blood-pressure; TTE: Transthoracic echocardiography; EP: Electrophysiologic study; ILR: Implantable loop recorder; TT: Head-up tilt table test.
Special tests in suspected vasovagal syncope

Tilt table test: In patients with unexplained syncope and ambiguous history for a vasovagal syncope, a tilt table test may help to support a diagnosis[2]. Fundamental to tilt testing is the ability to replicate the patient’s symptoms, during which critical observations of heart rate and blood pressure are documented[25]. A head-up tilt table test is a widely employed method in the diagnosis of syncopal disorders. Many investigations reported its usefulness in detecting neurally-mediated syncope[26]. Different tilt table protocols are introduced with variations in the initial stabilization phase, duration of tilting (20 to 45 min) and application of pharmacological agents[27,28]. Currently the most used protocols are the intravenous isoproterenol test, and the protocol using sublingual nitroglycerin[29,30]. Some protocols use adenosine[31], clomipramine[32] or alcohol[33] to provoke syncope. We use a method commonly known as the Westminster protocol, which was first introduced by Fitzpatrick et al[34]. After maintaining a supine position of 10 min the patient is tilted to a head-up angle of 60°. If symptoms are not proved within a few minutes sublingual nitroglycerin is administered as additional provocation. Using the same protocol, Raviele et al[35] observed a positive test response in 51% of patients with unexplained syncope; the test resulted in a specificity of 94%. In a recent analysis of pooled data published by Brignole, a positive head-up tilt table test was found in 62%-69% of patients with unexplained syncope, with a sensitivity of 94%[36]. Due to a lack of a gold standard, sensitivity and specificity of the tilt table test for patients with vasovagal syncope is not exactly known. Furthermore, the tilt table test presents several disadvantages. First, the test is time-consuming and requires experienced medical staff and appropriate technical equipment such that small clinics and general practitioners cannot perform this investigation. Second, the reproducibility of a positive head-up tilt table test varies enormously. Foglia-Manzillo et al[37] could reproduce a first positive head-up tilt table test in 77% of 34 patients, whereas Ruiz et al[38] found a reproducibility rate for the positive and negative head-up tilt table test of 54.5% and 84.3%, respectively. Third, several studies have shown that the mechanism of syncope during a tilt table test is not equivalent to that of a spontaneous syncope. For this reason, the tilt table test is not a useful method to determine therapeutic strategies for patients with vasovagal syncope.

The implantable loop recorder: The main goal of the evaluation of patients with syncope is to rule out cardiac arrhythmia as a marker of a high risk for cardiac death[15]. Continuous monitoring increases the likelihood of arrhythmia detection, with modern implantable loop recorders (ILRs) capable of continuous recording for up to 18 months. The ILR is implanted subcutaneously in the left hemithorax with automatic and patient-activated ECG-documentation modes available on most devices. Many studies have shown its value in detection of infrequent arrhythmias[39-41]. Current guidelines suggest ILR implantation for unexplained syncopes. In patients with vasovagal syncopes a significant cardioinhibitory reaction is seen in 25% and a mild decrease of the heart rate in 50% of all falls. Even documented asystole does not necessarily indicate that an anti-bradycardic therapy would result in symptoms relief, if the setting is typical for vasovagal syncope. Particularly in young patients, the question “when to implant” and “whom to implant” a pacemaker is often far from clear even with current trial evidence. We believe that a conservative pacing policy in younger patients without any evidence for structural heart disease or conduction disease is justifiable. In contrast every patient with a history of structural heart disease, unexplained syncope or high risk for cardiac arrhythmia may benefit from an ILR or a pacemaker.

The value and cost-effectiveness of ILR is well documented[42-44]. Implantation at an early stage in the investigation may reduce the costs of unnecessary investigations[45].

What treatment options do we have?

Once the diagnosis is clear the next questions that arise include, who needs therapy and what kind? Every patient benefits from information and education; some patients need medical therapy and only a few people need a pacemaker.

As there are many causes of syncope, a specific treatment cannot be administered without knowing the exact mechanism responsible for syncope. The main therapeutic innovations of the most recent years are isometric counter-pressure maneuver, lower limb compression bandage and therapy guided by external and ILR in patients with recurrent suspected neurally-mediated syncope. Most drugs are considered ineffective. However, some drugs such as midodrine and paroxetine showed positive results in patients with recurrent vasovagal syncope. The cornerstone of therapy for young patients with vasovagal syncope remains education and reassurance, except in rare and isolated cases of patients with a high frequency of recurrent episodes despite nonpharmacological measures. In the elderly, specific treatment is often necessary. In these patients, determination of the hemodynamic mechanism of spontaneous syncope by means of an external or implantable cardiac monitor seems to be the most advisable option for optimal management. Limited data exist for the role of drugs in the treatment of vasovagal syncope in older patients.

The main goal of treatment is to reduce syncope recurrence and physical trauma. However, patients with a single syncope without any high-risk occupations (e.g. professional drivers, pilots) may not necessarily need specific therapy. Clear education and counseling about the nature of the benign condition and how to avoid triggers may be sufficient. Patients with a high risk of recurrence or injury can be identified by risk scores and may require tailored treatment (Figure 3). Known risk factors for recurrent vasovagal syncope are the number of preceding syncopal spells and female gender[3]. In contrast, the head-up tilt test response has no predictive value (P = 0.881)[3].

Figure 3
Figure 3 Treatment of vasovagal syncope. SSRI: Selective serotonin reuptake inhibitors.
Non-medical therapy

An informative and instructive talk with the patient about the benign nature and prognosis is the first step in the treatment of patients with vasovagal syncope. Conditions triggering vasovagal reflexes should be avoided such as a hot environment, humid atmosphere, prolonged standing, and reduced water intake[2]. A reduction or cessation of vasoactive substances may be necessary[46]. Discontinuation of hypotensive drug treatment for concomitant conditions is an important first line measure for the prevention of syncope recurrences in many subjects, especially in older patients. Substitution of salt and intake of isotonic drinks expands the circulating blood volume and may improve venous return[47].

Patients should be motivated to identify prodromals of syncope. Lying or sitting down when initial symptoms appear may avert or attenuate syncope or traumatic falls.

Furthermore counterpressure maneuvers such as hand-grip and leg crossing may inhibit vasovagal syncope by increasing the venous return[48]. Leg crossing combined with tensing of muscles at the onset of prodromal symptoms can delay or even prevent vasovagal syncope[48]. A more complex and time-consuming concept is that of tilt training: orthostatic training was found to significantly improve symptoms in adolescents with neurocardiogenic syncope[49]. Twice-a-day training sessions of 40 min tilt positioning at home by standing against a wall significantly reduced the incidence of recurrence[49]. However, the compliance in a tilt training program is rather low[50,51] and no long-term data are available.

Pharmacological therapy

A number of drugs have been tested in the treatment of vasovagal syncope. These have included β-blockers, disopyramide, scopolamine, theophylline, ephedrine, etilefrine, midodrine, clonidine, and serotonin reuptake inhibitors (SRI)[2]. Actually, no convincing data exist to support the use of one over another as a first line therapy. There is only limited data from placebo-controlled trials.

β-blockers:β-blockers have been the first choice for many years. Several small non-randomized, uncontrolled trials have shown a benefit, supporting the pathophysiological concept that β-blockers reduce sympathetic activity and avoid an “overshooting” vagal reaction[52]. However, there was no positive outcome in randomized, long-term, controlled trials for metoprolol[53], propanol, nadolol[54] or atenolol[55]. According the guidelines of the European Society of Cardiology, β-blockers should not be used to treat reflex syncope[2].

Midodrine: Midodrine, an alpha-agonist vasoconstrictor, affects smooth muscle cells both in arteries and veins without effecting heart rhythm or negative inotropy. There is no effect on the central nervous system. It is metabolized to the active drug desglymidodrine[56]. It has to be administered 3 times per day starting with 5 mg, because of a half-life of only 2-3 h. In 3 small randomized, placebo-controlled trials, midodrine had a beneficial effect on symptom frequency, symptoms during head-up tilt, and quality of life[57-59] (Table 1). Ward et al[57] evaluated 16 patients (mean age 56 years) in a 2 × 2 crossover trial: group 1 received placebo for the first 28 d (period 1) and midodrine for the second 28 d (period 2); while group 2 received midodrine for period 1 and placebo for period 2. Patients treated with midodrine showed more symptom-free days (P < 0.0001), a higher quality of life and fewer positive tilt testing results (P = 0.01).

Table 1 Midodrine: randomized placebo-controlled trials.
Author, yearnFollow-up periodEndpointP
Ward et al[57], 1998161 moTT0.01
Perez-Lugones et al[58], 2001616 moSyncope recurrence< 0.01
Kaufmann et al[59], 2002121 wkTT< 0.02
Qingyou et al[60], 20062642 moTT< 0.05

However, these patients probably had overlap with some forms of orthostatic hypotension. In an acute double-blind placebo-controlled tilt study performed in 12 patients with a history of neurally-mediated syncope, Kaufmann et al[59] (Table 1) reported that a positive tilt result was observed in 67% of patients in the placebo group vs 17% of patients in the active medication group. The patients were randomized to receive a nonpressor dose of midodrine (5 mg) or placebo on day 1 and the opposite on day 3. One hour after drug or placebo administration, patients underwent 60-degree head-up tilt lasting 40 min (unless hypotension or bradycardia developed first). Positive results were also obtained in one small randomized trial of pediatric patients. These data suggest that midodrine is more effective in the treatment of orthostatic hypotension caused by autonomic dysfunction than in the neurally-mediated syncope. The available data are still insufficient to prove an efficacy of midodrine in vasovagal syncope. Midodrine may be indicated in patients with frequent vasovagal syncope refractory to lifestyle measures (recommendation IIB, level B)[2] (Figure 3).

Serotonin reuptake inhibitors: In contrast to vasoconstrictors, SRI may reduce the central sympathetic nervous system activity[61]. Some open-label studies and one randomized, placebo-controlled trial demonstrated that SRI may reduce recurrent vasovagal syncope: during a follow-up of 25 mo, 17.6% of patients who randomly received paroxetine had syncope recurrence compared to 52.9% of the placebo group (P < 0.001)[62], although fluoxetine failed to show a significant reduction compared to propanolol[63] (Table 2). However Takata et al[64] reported that paroxetine does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers. Until the result of the study is confirmed by other trials, use of this drug cannot be recommended.

Table 2 Selective serotonin reuptake inhibitors: randomized placebo-controlled trials.
Author, yearnDrugFollow-up periodEndpointP
Theodorakis et al[63], 200696Fluoxetine6 moTime to vasovagal episode< 0.05
Syncope episodesNS
Di Girolamo et al[62], 199968Paroxetine6 moTT< 0.001
Syncope recurrence0.001
Cardiac pacing

The role of cardiac pacing is controversial. Non-placebo-controlled trials (VPS I, VASIS, SYDIT) showed some benefit with dual-chamber pacing in reducing syncope recurrence[65-67] (Table 3). However, placebo-controlled trials in which all patients received a dual-chamber pacemaker and were randomly assigned to DDD or 0D0-Mode could not reproduce these results (VPS II, SYNPACE)[68,69] (Table 3). A recently published meta-analysis of all studies suggested a non-significant 17% reduction in syncope from the double-blinded studies, and an 84% reduction in the studies where the control group did not receive a pacemaker[70]. In conclusion, the results of small, initial trials have overrated the treatment effect of pacemakers due to a lack of blinding of physicians and patients. Blinded trials suggest that the apparent effect is due to a strong expectation response to pacing[70].

Table 3 Pacemaker-therapy: randomized trials.
Author, yearTrialnDesignFollow-up period (yr)EndpointP
Conolly et al[65], 1999VPS I54No placebo1Syncope recurrence< 0.001
Sutton et al[66], 2000VASIS42No placebo3.7Syncope recurrence< 0.001
Ammirati et al[67], 2001SYDIT93No placebo1.5Syncope recurrence 0.004
Conolly et al[68], 2003VPS II100Placebo0.5Syncope recurrenceNS
Raviele et al[69], 2004SYNPACE29Placebo2 yrSyncope recurrenceNS

ILRs may identify patients with severe cardioinhibitory vasovagal syncope and hence a better detection rate may identify responders to pacing more accurately. This is supported by the observation that patients with syncope associated with abrupt bradycardia displayed a better response to cardiac pacing therapy than those with gradual onset bradycardia[71]. The syncope burden decreased from 2.7 per year to 0.45 per year (P < 0.02)[71]. A larger trial, the ISSUE 2 study, hypothesized that spontaneous asystole and not tilt test results should form the basis for patient selection for pacemaker therapy. This study followed 392 patients with presumed reflex syncope with an ILR. Patients with ILR-guided therapy, predominantly pacing for asystole, experienced a reduction in recurrence of syncope compared to non-ILR-guided therapy (10% vs 41%, P < 0.002). It is noteworthy that ISSUE 2 was not a randomized trial in contrast to the ongoing ISSUE 3 study which will give new insights into ILR-guided pacemaker therapy in vasovagal syncope[72].

Given a IIa/B classification by the European Society of Cardiology, pacemaker implantation may play a role in special circumstances. It should be considered in patients with frequent recurrent reflex syncope, e.g. when no prodromes occur, an age > 40 years and documented spontaneous bradycardia or asystole during monitoring[2].


The management of vasovagal syncope is evolving. The pathophysiology of vasovagal syncope is not fully understood. Non-pharmacological treatment options are a fundamental first step of all treatment pathways. Only limited data exist showing a modest benefit using midodrine or SRI for recurrent vasovagal syncope. An ILR is a useful tool to detect or exclude hazardous cardiac arrhythmia.


Peer reviewer: Nunzia Rosa Petix, MD, Cardiology Department, S.Giuseppe Hospital, Viale Boccaccio 2, Empoli, 50053 Florence, Italy

S- Editor Cheng JX L- Editor Cant MR E- Editor Zheng XM

1.  Savage DD, Corwin L, McGee DL, Kannel WB, Wolf PA. Epidemiologic features of isolated syncope: the Framingham Study. Stroke. 1985;16:626-629.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, Deharo JC, Gajek J, Gjesdal K, Krahn A. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J. 2009;30:2631-2671.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Aydin MA, Maas R, Mortensen K, Steinig T, Klemm H, Risius T, Meinertz T, Willems S, Morillo CA, Ventura R. Predicting recurrence of vasovagal syncope: a simple risk score for the clinical routine. J Cardiovasc Electrophysiol. 2009;20:416-421.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Brignole M, Menozzi C, Del Rosso A, Costa S, Gaggioli G, Bottoni N, Bartoli P, Sutton R. New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification. Analysis of the pre-syncopal phase of the tilt test without and with nitroglycerin challenge. Vasovagal Syncope International Study. Europace. 2000;2:66-76.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Ganzeboom KS, Colman N, Reitsma JB, Shen WK, Wieling W. Prevalence and triggers of syncope in medical students. Am J Cardiol. 2003;91:1006-1008, A8.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Brignole M, Alboni P, Benditt D, Bergfeldt L, Blanc JJ, Bloch Thomsen PE, van Dijk JG, Fitzpatrick A, Hohnloser S, Janousek J. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J. 2001;22:1256-1306.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Soteriades ES, Evans JC, Larson MG, Chen MH, Chen L, Benjamin EJ, Levy D. Incidence and prognosis of syncope. N Engl J Med. 2002;347:878-885.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Alboni P, Brignole M, Menozzi C, Raviele A, Del Rosso A, Dinelli M, Solano A, Bottoni N. Diagnostic value of history in patients with syncope with or without heart disease. J Am Coll Cardiol. 2001;37:1921-1928.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Brignole M, Alboni P, Benditt DG, Bergfeldt L, Blanc JJ, Bloch Thomsen PE, van Dijk JG, Fitzpatrick A, Hohnloser S, Janousek J. Guidelines on management (diagnosis and treatment) of syncope--update 2004. Europace. 2004;6:467-537.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Colman N, Nahm K, Ganzeboom KS, Shen WK, Reitsma J, Linzer M, Wieling W, Kaufmann H. Epidemiology of reflex syncope. Clin Auton Res. 2004;14 Suppl 1:9-17.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Ammirati F, Colaceci R, Cesario A, Strano S, Della Scala A, Colangelo I, De Santo T, Toscano E, Ricci R, Santini M. Management of syncope: clinical and economic impact of a Syncope Unit. Europace. 2008;10:471-476.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Alboni P, Tomasi C, Menozzi C, Bottoni N, Paparella N, Fucà G, Brignole M, Cappato R. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001;37:548-553.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Serletis A, Rose S, Sheldon AG, Sheldon RS. Vasovagal syncope in medical students and their first-degree relatives. Eur Heart J. 2006;27:1965-1970.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Tan MP, Parry SW. Vasovagal syncope in the older patient. J Am Coll Cardiol. 2008;51:599-606.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Kapoor WN. Current evaluation and management of syncope. Circulation. 2002;106:1606-1609.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Hainsworth R. Pathophysiology of syncope. Clin Auton Res. 2004;14 Suppl 1:18-24.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Shalev Y, Gal R, Tchou PJ, Anderson AJ, Avitall B, Akhtar M, Jazayeri MR. Echocardiographic demonstration of decreased left ventricular dimensions and vigorous myocardial contraction during syncope induced by head-up tilt. J Am Coll Cardiol. 1991;18:746-751.  [PubMed]  [DOI]  [Cited in This Article: ]
18.  Mark AL. The Bezold-Jarisch reflex revisited: clinical implications of inhibitory reflexes originating in the heart. J Am Coll Cardiol. 1983;1:90-102.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Benditt DG, Ermis C, Padanilam B, Samniah N, Sakaguchi S. Catecholamine response during haemodynamically stable upright posture in individuals with and without tilt-table induced vasovagal syncope. Europace. 2003;5:65-70.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Grubb BP, Kosinski D. Dysautonomic and reflex syncope syndromes. Cardiol Clin. 1997;15:257-268.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Flevari P, Leftheriotis D, Komborozos C, Fountoulaki K, Dagres N, Theodorakis G, Kremastinos D. Recurrent vasovagal syncope: comparison between clomipramine and nitroglycerin as drug challenges during head-up tilt testing. Eur Heart J. 2009;30:2249-2253.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Grubb BP. Clinical practice. Neurocardiogenic syncope. N Engl J Med. 2005;352:1004-1010.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Morillo CA. Evidence-based common sense: the role of clinical history for the diagnosis of vasovagal syncope. Eur Heart J. 2006;27:253-254.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Sheldon R, Rose S, Connolly S, Ritchie D, Koshman ML, Frenneaux M. Diagnostic criteria for vasovagal syncope based on a quantitative history. Eur Heart J. 2006;27:344-350.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Grubb BP, Kosinski D. Tilt table testing: concepts and limitations. Pacing Clin Electrophysiol. 1997;20:781-787.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Kenny RA, Ingram A, Bayliss J, Sutton R. Head-up tilt: a useful test for investigating unexplained syncope. Lancet. 1986;1:1352-1355.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  Raviele A, Gasparini G, Di Pede F, Menozzi C, Brignole M, Dinelli M, Alboni P, Piccolo E. Nitroglycerin infusion during upright tilt: a new test for the diagnosis of vasovagal syncope. Am Heart J. 1994;127:103-111.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Sheldon R, Koshman ML. A randomized study of tilt test angle in patients with undiagnosed syncope. Can J Cardiol. 2001;17:1051-1057.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Graham LA, Gray JC, Kenny RA. Comparison of provocative tests for unexplained syncope: isoprenaline and glyceryl trinitrate for diagnosing vasovagal syncope. Eur Heart J. 2001;22:497-503.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Shen WK, Jahangir A, Beinborn D, Lohse CM, Hodge DO, Rea RF, Hammill SC. Utility of a single-stage isoproterenol tilt table test in adults: a randomized comparison with passive head-up tilt. J Am Coll Cardiol. 1999;33:985-990.  [PubMed]  [DOI]  [Cited in This Article: ]
31.  Mittal S, Stein KM, Markowitz SM, Slotwiner DJ, Rohatgi S, Lerman BB. Induction of neurally mediated syncope with adenosine. Circulation. 1999;99:1318-1324.  [PubMed]  [DOI]  [Cited in This Article: ]
32.  Theodorakis GN, Livanis EG, Leftheriotis D, Flevari P, Markianos M, Kremastinos DT. Head-up tilt test with clomipramine challenge in vasovagal syndrome--a new tilt testing protocol. Eur Heart J. 2003;24:658-663.  [PubMed]  [DOI]  [Cited in This Article: ]
33.  Tateoka K, Iwasaki YK, Ono T, Kobayashi Y, Katoh T, Takano T. A new alcohol provocation head up tilt protocol in the patients with alcohol-related syncope. Europace. 2007;9:220-224.  [PubMed]  [DOI]  [Cited in This Article: ]
34.  Fitzpatrick AP, Theodorakis G, Vardas P, Sutton R. Methodology of head-up tilt testing in patients with unexplained syncope. J Am Coll Cardiol. 1991;17:125-130.  [PubMed]  [DOI]  [Cited in This Article: ]
35.  Raviele A, Menozzi C, Brignole M, Gasparini G, Alboni P, Musso G, Lolli G, Oddone D, Dinelli M, Mureddu R. Value of head-up tilt testing potentiated with sublingual nitroglycerin to assess the origin of unexplained syncope. Am J Cardiol. 1995;76:267-272.  [PubMed]  [DOI]  [Cited in This Article: ]
36.  Brignole M, Alboni P, Benditt DG, Bergfeldt L, Blanc JJ, Thomsen PE, Gert van Dijk J, Fitzpatrick A, Hohnloser S, Janousek J. Guidelines on management (diagnosis and treatment) of syncope-update 2004. Executive Summary. Eur Heart J. 2004;25:2054-2072.  [PubMed]  [DOI]  [Cited in This Article: ]
37.  Foglia-Manzillo G, Giada F, Beretta S, Corrado G, Santarone M, Raviele A. Reproducibility of head-up tilt testing potentiated with sublingual nitroglycerin in patients with unexplained syncope. Am J Cardiol. 1999;84:284-288.  [PubMed]  [DOI]  [Cited in This Article: ]
38.  Ruiz GA, Scaglione J, González-Zuelgaray J. Reproducibility of head-up tilt test in patients with syncope. Clin Cardiol. 1996;19:215-220.  [PubMed]  [DOI]  [Cited in This Article: ]
39.  Krahn AD, Klein GJ, Yee R, Norris C. Final results from a pilot study with an implantable loop recorder to determine the etiology of syncope in patients with negative noninvasive and invasive testing. Am J Cardiol. 1998;82:117-119.  [PubMed]  [DOI]  [Cited in This Article: ]
40.  Pezawas T, Stix G, Kastner J, Schneider B, Wolzt M, Schmidinger H. Implantable loop recorder in unexplained syncope: classification, mechanism, transient loss of consciousness and role of major depressive disorder in patients with and without structural heart disease. Heart. 2008;94:e17.  [PubMed]  [DOI]  [Cited in This Article: ]
41.  Brignole M, Sutton R, Wieling W, Lu SN, Erickson MK, Markowitz T, Grovale N, Ammirati F, Benditt DG. Analysis of rhythm variation during spontaneous cardioinhibitory neurally-mediated syncope. Implications for RDR pacing optimization: an ISSUE 2 substudy. Europace. 2007;9:305-311.  [PubMed]  [DOI]  [Cited in This Article: ]
42.  Krahn AD, Klein GJ, Yee R, Manda V. The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope. Am Heart J. 1999;137:870-877.  [PubMed]  [DOI]  [Cited in This Article: ]
43.  Solano A, Menozzi C, Maggi R, Donateo P, Bottoni N, Lolli G, Tomasi C, Croci F, Oddone D, Puggioni E. Incidence, diagnostic yield and safety of the implantable loop-recorder to detect the mechanism of syncope in patients with and without structural heart disease. Eur Heart J. 2004;25:1116-1119.  [PubMed]  [DOI]  [Cited in This Article: ]
44.  Farwell DJ, Freemantle N, Sulke N. The clinical impact of implantable loop recorders in patients with syncope. Eur Heart J. 2006;27:351-356.  [PubMed]  [DOI]  [Cited in This Article: ]
45.  Kürer CC. Implantable loop recorders. dollars and sense. J Am Coll Cardiol. 2003;42:502-504.  [PubMed]  [DOI]  [Cited in This Article: ]
46.  Gaggioli G, Bottoni N, Mureddu R, Foglia-Manzillo G, Mascioli G, Bartoli P, Musso G, Menozzi C, Brignole M. Effects of chronic vasodilator therapy to enhance susceptibility to vasovagal syncope during upright tilt testing. Am J Cardiol. 1997;80:1092-1094.  [PubMed]  [DOI]  [Cited in This Article: ]
47.  El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart. 1996;75:134-140.  [PubMed]  [DOI]  [Cited in This Article: ]
48.  van Dijk N, Quartieri F, Blanc JJ, Garcia-Civera R, Brignole M, Moya A, Wieling W. Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the Physical Counterpressure Manoeuvres Trial (PC-Trial). J Am Coll Cardiol. 2006;48:1652-1657.  [PubMed]  [DOI]  [Cited in This Article: ]
49.  Di Girolamo E, Di Iorio C, Leonzio L, Sabatini P, Barsotti A. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study. Circulation. 1999;100:1798-1801.  [PubMed]  [DOI]  [Cited in This Article: ]
50.  Foglia-Manzillo G, Giada F, Gaggioli G, Bartoletti A, Lolli G, Dinelli M, Del Rosso A, Santarone M, Raviele A, Brignole M. Efficacy of tilt training in the treatment of neurally mediated syncope. A randomized study. Europace. 2004;6:199-204.  [PubMed]  [DOI]  [Cited in This Article: ]
51.  Reybrouck T, Heidbüchel H, Van De Werf F, Ector H. Long-term follow-up results of tilt training therapy in patients with recurrent neurocardiogenic syncope. Pacing Clin Electrophysiol. 2002;25:1441-1446.  [PubMed]  [DOI]  [Cited in This Article: ]
52.  Ventura R, Maas R, Zeidler D, Schoder V, Nienaber CA, Schuchert A, Meinertz T. A randomized and controlled pilot trial of beta-blockers for the treatment of recurrent syncope in patients with a positive or negative response to head-up tilt test. Pacing Clin Electrophysiol. 2002;25:816-821.  [PubMed]  [DOI]  [Cited in This Article: ]
53.  Sheldon R, Connolly S, Rose S, Klingenheben T, Krahn A, Morillo C, Talajic M, Ku T, Fouad-Tarazi F, Ritchie D. Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation. 2006;113:1164-1170.  [PubMed]  [DOI]  [Cited in This Article: ]
54.  Flevari P, Livanis EG, Theodorakis GN, Zarvalis E, Mesiskli T, Kremastinos DT. Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being. J Am Coll Cardiol. 2002;40:499-504.  [PubMed]  [DOI]  [Cited in This Article: ]
55.  Madrid AH, Ortega J, Rebollo JG, Manzano JG, Segovia JG, Sánchez A, Peña G, Moro C. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study. J Am Coll Cardiol. 2001;37:554-559.  [PubMed]  [DOI]  [Cited in This Article: ]
56.  Calkins H. Pharmacologic approaches to therapy for vasovagal syncope. Am J Cardiol. 1999;84:20Q-25Q.  [PubMed]  [DOI]  [Cited in This Article: ]
57.  Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of neurocardiogenic syncope. Heart. 1998;79:45-49.  [PubMed]  [DOI]  [Cited in This Article: ]
58.  Perez-Lugones A, Schweikert R, Pavia S, Sra J, Akhtar M, Jaeger F, Tomassoni GF, Saliba W, Leonelli FM, Bash D. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. J Cardiovasc Electrophysiol. 2001;12:935-938.  [PubMed]  [DOI]  [Cited in This Article: ]
59.  Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study. Ann Neurol. 2002;52:342-345.  [PubMed]  [DOI]  [Cited in This Article: ]
60.  Qingyou Z, Junbao D, Chaoshu T. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr. 2006;149:777-780.  [PubMed]  [DOI]  [Cited in This Article: ]
61.  Grubb BP, Karas BJ. The potential role of serotonin in the pathogenesis of neurocardiogenic syncope and related autonomic disturbances. J Interv Card Electrophysiol. 1998;2:325-332.  [PubMed]  [DOI]  [Cited in This Article: ]
62.  Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1999;33:1227-1230.  [PubMed]  [DOI]  [Cited in This Article: ]
63.  Theodorakis GN, Leftheriotis D, Livanis EG, Flevari P, Karabela G, Aggelopoulou N, Kremastinos DT. Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study. Europace. 2006;8:193-198.  [PubMed]  [DOI]  [Cited in This Article: ]
64.  Takata TS, Wasmund SL, Smith ML, Li JM, Joglar JA, Banks K, Kowal RC, Page RL, Hamdan MH. Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers. Circulation. 2002;106:1500-1504.  [PubMed]  [DOI]  [Cited in This Article: ]
65.  Connolly SJ, Sheldon R, Roberts RS, Gent M. The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol. 1999;33:16-20.  [PubMed]  [DOI]  [Cited in This Article: ]
66.  Sutton R, Brignole M, Menozzi C, Raviele A, Alboni P, Giani P, Moya A. Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope : pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators. Circulation. 2000;102:294-299.  [PubMed]  [DOI]  [Cited in This Article: ]
67.  Ammirati F, Colivicchi F, Santini M. Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope: a multicenter, randomized, controlled trial. Circulation. 2001;104:52-57.  [PubMed]  [DOI]  [Cited in This Article: ]
68.  Connolly SJ, Sheldon R, Thorpe KE, Roberts RS, Ellenbogen KA, Wilkoff BL, Morillo C, Gent M. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA. 2003;289:2224-2229.  [PubMed]  [DOI]  [Cited in This Article: ]
69.  Raviele A, Giada F, Menozzi C, Speca G, Orazi S, Gasparini G, Sutton R, Brignole M. A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE). Eur Heart J. 2004;25:1741-1748.  [PubMed]  [DOI]  [Cited in This Article: ]
70.  Sud S, Massel D, Klein GJ, Leong-Sit P, Yee R, Skanes AC, Gula LJ, Krahn AD. The expectation effect and cardiac pacing for refractory vasovagal syncope. Am J Med. 2007;120:54-62.  [PubMed]  [DOI]  [Cited in This Article: ]
71.  Sud S, Klein GJ, Skanes AC, Gula LJ, Yee R, Krahn AD. Implications of mechanism of bradycardia on response to pacing in patients with unexplained syncope. Europace. 2007;9:312-318.  [PubMed]  [DOI]  [Cited in This Article: ]
72.  Brignole M. International study on syncope of uncertain aetiology 3 (ISSUE 3): pacemaker therapy for patients with asystolic neurally-mediated syncope: rationale and study design. Europace. 2007;9:25-30.  [PubMed]  [DOI]  [Cited in This Article: ]